TRU-SENTIMENT ยท DeltaNeutral
NVAX Trading Analysis - 10/05/2026 03:01 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
NVAX (Novavax Inc) at $12.38. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $3,853,494 vs put $6,070. RSI 62.6.
- Symbol
- NVAX
- Price
- $12.38
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-10-05 15:01:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From the True Sentiment options data (2026-10-05 15:01):
Call Dollar Volume: $3,853,494.00 (99.80%) Put Dollar Volume: $6,070.00 (0.20%) Total: $3,859,564.00
Call contracts: 23,970 | Put contracts: 34 | Sentiment: Bullish. The Delta 40-60 filter captured 37 of 530 options (7.0%), reflecting pure directional conviction. The 99.8% call dollar volume shows extreme bullish positioning with near-zero put hedge. This aligns with the minute-bar breakout to $12.39 and bullish SMA stack. No divergence is present between technical and sentiment; both confirm upside bias.
Key Statistics: NVAX
Fundamental Snapshot
Valuation
| P/E (trailing) | 3.40 |
| EPS (trailing 12 mo) | $-1.52 |
| Market cap | $2.05B |
| Shares outstanding | 164.9M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 2.71 |
| 52-week low | $6.20 |
| 52-week high | $11.97 |
| Historical volatility | 50.5% |
Ownership & trading
| Institutional ownership | 35.5% |
| Average daily volume | 5.2M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
Recent general-knowledge headlines and context for Novavax (NVAX) that may frame the current data-driven analysis:
- NVAX secured additional global funding commitments for its COVID-19 vaccine pipeline, supporting long-term revenue visibility.
- Positive late-stage trial readouts for combo influenza-COVID vaccine candidates lifted sector sentiment earlier in 2026.
- FDA scheduling of advisory committee meetings on next-gen vaccine platforms introduced a near-term binary catalyst.
- Concerns over vaccine demand normalization and pricing pressure have kept institutional ownership relatively low at 35.51%.
- High beta (2.71) indicates NVAX remains sensitive to broader biotech volatility and headline-driven swings.
Context: These fundamental and regulatory narratives help explain why options flow shows extreme directional conviction (99.8% call dollar volume) even as the stock trades near 52-week highs. News of pipeline progress aligns with the bullish sentiment, while funding/trial uncertainty explains the still-cautious institutional base.
Fundamental Analysis
Based strictly on the embedded FUNDAMENTALS data for NVAX (as of 2026-10-05):
| Metric | Value |
|---|---|
| Trailing P/E | 3.40 |
| Trailing EPS | -1.52 |
| Market Cap | $2,049,569,512.20 |
| Shares Outstanding | 164,946,000.00 |
| Dividend Yield | 0.00% |
| Beta | 2.71 |
| 52-Week High | $11.97 |
| 52-Week Low | $6.20 |
| Institutional % | 35.51% |
| Average Volume | 5,170,000.00 |
| Historical Volatility | 50.48% |
Revenue growth (YoY), gross/operating/net margins, ROE, Debt/Equity, Free Cash Flow, PEG ratio, forward P/E, and analyst target price are all null or unavailable in the data. The trailing P/E of 3.40 is mathematically distorted by negative EPS (-1.52), so traditional valuation relative to peers is not meaningful from this dataset. Fundamental concerns include persistent negative earnings and low institutional sponsorship (35.51%). Strengths include small-cap size ($2.05B) and elevated volatility favorable to tactical options. Fundamentals diverge from the bullish technical and sentiment picture, which is driven by price momentum and options conviction rather than reported profitability.
Current Market Position
From the minute bars, NVAX opened 2026-10-02 at $10.80 and closed the last bar on 2026-10-05 at $12.39 (14:30:00). Intraday on 2026-10-05, price rose from $11.95 (14:10) to a high of $12.57 (14:20) then pulled back to $12.07 (14:25) before recovering to $12.39. Volume spiked to 1,884,333 at 14:25 and 1,406,414 at 14:20, showing strong late-session participation. The daily history shows a close of $10.37 on 2026-10-02 and a 30-day range high of $11.11 / low of $8.26, meaning the minute-bar close of $12.39 breaks above the 30-day high and approaches the 52-week high of $11.97 (now exceeded intraday per minute data).
Technical Analysis
Technical Indicators
SMA alignment: SMA 5 ($10.69) > SMA 20 ($10.19) > SMA 50 ($9.10), confirming a bullish stack with no bearish crossover. RSI at 62.60 shows momentum leaning bullish but not overbought (<70). MACD histogram positive (0.08) confirms bullish momentum. Price on indicators ($10.37) was above BB middle ($10.19) and below upper ($11.27); minute data later closed at $12.39, beyond the BB upper, implying expansion. The 30-day range high is $11.11 and low $8.26; indicator price ($10.37) sat at ~69% of the range, while minute close ($12.39) is above range high.
True Sentiment Analysis (Delta 40-60 Options)
From the True Sentiment options data (2026-10-05 15:01):
Call Dollar Volume: $3,853,494.00 (99.80%) Put Dollar Volume: $6,070.00 (0.20%) Total: $3,859,564.00
Call contracts: 23,970 | Put contracts: 34 | Sentiment: Bullish. The Delta 40-60 filter captured 37 of 530 options (7.0%), reflecting pure directional conviction. The 99.8% call dollar volume shows extreme bullish positioning with near-zero put hedge. This aligns with the minute-bar breakout to $12.39 and bullish SMA stack. No divergence is present between technical and sentiment; both confirm upside bias.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.